GMAB
Genmab A/S
NASDAQ · Healthcare · Biotechnology · DK
$33.60
−2.35%Margins
Gross margin
93.0%
EBITDA margin
29.5%
EBIT margin
32.3%
Net margin
19.1%
FCF margin
21.0%
13.2%
Return on equity
6.3%
Return on assets
11.9%
Return on invested capital
0.33x
Asset turnover
$890.3M
Cash from operations
$2.45
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026